| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,280,000 |
| Market
Cap: |
106.35(M) |
| Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,771 |
| 52
Week Range: |
$2.25 - $7.96 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.6 |
| Insider 6 Months : 14.8 |
| Insider 3/6 Months : 23.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53,764 |
357,764 |
382,819 |
550,734 |
| Total Buy Value |
$200,002 |
$981,272 |
$1,081,809 |
$1,702,202 |
| Total People Bought |
2 |
6 |
8 |
9 |
| Total Buy Transactions |
2 |
8 |
10 |
16 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Koplewicz Harold S |
Director |
– • – |
2009-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,485 |
60,485 |
|
- |
|
| Contag Pamela Reilly |
Director |
– • – |
2009-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,485 |
5,485 |
|
- |
|
| Philips Laura A |
Director |
– • – |
2009-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,485 |
44,485 |
|
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2009-12-10 |
4 |
A |
$0.00 |
$0 |
D/D |
5,485 |
40,485 |
|
- |
|
| Philips Laura A |
Director |
– • – |
2009-11-18 |
4 |
B |
$3.60 |
$25,200 |
D/D |
7,000 |
39,000 |
2.39 |
- |
|
| Stoll Roger G Phd |
Director |
– • – |
2009-11-18 |
4 |
B |
$3.60 |
$90,000 |
D/D |
25,000 |
35,000 |
2.39 |
- |
|
| Hobbs Eamonn P |
President and CEO |
• • – |
2009-11-18 |
4 |
B |
$3.60 |
$360,000 |
D/D |
100,000 |
100,000 |
2.81 |
- |
|
| Kandarpa Krishna |
Exec. V.P., Chief Medical Off. |
• – – |
2009-10-20 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Mcdonald David |
Chief Financial Officer |
• – – |
2009-09-14 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Taney Richard |
Director |
– • – |
2009-07-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
25,000 |
206,000 |
|
- |
|
| Keck Barbra |
Controller |
• – – |
2009-05-12 |
4 |
B |
$3.24 |
$3,240 |
D/D |
1,000 |
1,000 |
2.66 |
- |
|
| Ladd Robert |
Director |
– • – |
2008-12-31 |
4 |
S |
$1.19 |
$498,581 |
I/I |
(418,976) |
2,382,863 |
|
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
181,000 |
|
- |
|
| Rifkin Jason Andrew |
Sr. VP Clinical Oper. & SecyOf |
• – – |
2008-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,135 |
|
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-12-09 |
4/A |
A |
$0.00 |
$0 |
D/D |
20,000 |
181,000 |
|
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-11-13 |
4 |
B |
$0.89 |
$8,900 |
D/D |
10,000 |
161,000 |
2.81 |
- |
|
| Philips Laura A |
Director |
– • – |
2008-11-07 |
4 |
B |
$1.01 |
$10,284 |
D/D |
10,000 |
32,000 |
2.39 |
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-07-20 |
4 |
A |
$2.44 |
$61,000 |
D/D |
25,000 |
151,000 |
|
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-07-02 |
4/A |
A |
$2.44 |
$61,000 |
D/D |
25,000 |
151,000 |
|
- |
|
| Lewis Jonathan |
Director |
– • – |
2008-06-30 |
4 |
A |
$2.47 |
$24,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Koplewicz Harold S |
Director |
– • – |
2008-06-30 |
4 |
A |
$2.47 |
$24,700 |
D/D |
10,000 |
55,000 |
|
- |
|
| Philips Laura A |
Director |
– • – |
2008-06-30 |
4 |
A |
$2.47 |
$24,700 |
D/D |
10,000 |
22,000 |
|
- |
|
| Ladd Robert |
Director |
– • • |
2008-06-30 |
4 |
A |
$2.47 |
$24,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Taney Richard |
Chief Executive Officer |
• • – |
2008-06-10 |
4 |
A |
$2.19 |
$21,900 |
D/D |
10,000 |
126,000 |
|
- |
|
| Philips Laura A |
Director |
– • – |
2008-05-23 |
4 |
B |
$1.69 |
$17,334 |
D/D |
10,000 |
12,000 |
2.39 |
- |
|
370 Records found
|
|
Page 9 of 15 |
|
|
0.23 (3.2%) 
